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ABSTRACT Since the publication of the new Global Initiative for Chronic Obstructive Lung Disease
(GOLD) proposal for the assessment of chronic obstructive lung disease (COPD), four studies have used
existing cohorts to explore the characteristics, temporal variability and/or relationship with outcomes of the
four resulting patient categories (A, B, C and D).
Here, we compare their results and address a number of frequently asked questions (FAQs) on the topic.
The most salient findings were that: 1) the prevalence of these four groups depends on the specific
population studied, C being the least prevalent; 2) comorbidities are particularly prevalent in the two ‘‘high-
symptom’’ groups (B and D); 3) patients classifiedZ as A or D tend to remain in the same group over time,
whereas those classified as B or C change substantially during follow-up; 4) mortality at 3 years was lowest
in A and worst in D but surprisingly similar (and intermediate) in B and C; and 5) the incidence of
exacerbations during follow-up increases progressively from A to D but that of hospitalisations behave
similarly to mortality.
These results identify several strengths and shortcomings of the new GOLD assessment proposal,
particularly that group B is associated with more morbidity and high mortality.
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The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has recently proposed a new
multidimensional system for the assessment and management of patients with chronic obstructive
pulmonary disease (COPD) that combines the impact of the disease as perceived by the patient with the
severity of airflow limitation and the past history of exacerbations [1]. As a result, COPD patients are now
classified in four categories or groups (A, B, C and D) (fig. 1) that, along with the assessment of potential
comorbidities, can assist in guiding their therapy [1].
This proposal was based on the recognition that COPD is a complex and heterogeneous disease and that the
severity of airflow limitation (assessed by measuring forced expiratory volume in 1 s (FEV1)) is poorly
related to many other clinically relevant aspects of the disease [7]. In addition, recent trials have shown that
the arbitrary cut-off values for FEV1 did not match the application of pharmacological treatment. However,
the revised GOLD strategy is an empirical proposal mostly based on expert opinion, as available evidence
refers to management but not assessment of the disease and the studies providing evidence have classified
patients according to the previous GOLD recommendations, which were based almost exclusively on FEV1
[8] with or without a history of exacerbations. Not surprisingly, therefore, soon after the release of this new
GOLD proposal, a number of investigators rushed to explore, in their existing cohorts (i.e. COPDGene [2],
Copenhagen [3], Collaborative Cohorts to assess Multicomponent Indices of COPD in Spain [4] and
ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) [5]), the
distribution, characteristics, temporal stability and/or relationship with long-term outcomes of these four
patient categories. In this article, we: 1) review and compare the results of these four studies (table 1); and
2) list a number of frequently asked questions (FAQs) about this GOLD assessment proposal and provide
some answers based on these published results. Overall, this review provides a global view of the strengths
and limitations of the new GOLD recommendations [1].
The GOLD 2011 assessment proposal
The GOLD 2011 assessment proposal of COPD includes two dimensions: the impact of the disease as
perceived by the patient and the risk of future exacerbations (fig. 1) [1]. To classify patients into the ‘‘low-
symptom’’ or ‘‘high-symptom’’ groups, GOLD 2011 recommends the use of the modified Medical Research
Council (mMRC) scale of breathlessness (,2 or o2, respectively) or the COPD Assessment Test (CAT)
(,10 or o10, respectively). To assess the risk of future exacerbations, GOLD 2011 suggests the use of two
different (and poorly correlated) criteria: the severity of airflow limitation, as assessed by FEV1 (,50%
predicted), and the previous individual history of exacerbations (two or more exacerbations per year, or one
or more hospitalisation per year) [1]. Whenever there is a discrepancy between the risk category, as assessed
by the FEV1, and/or the exacerbation history, the variable indicating the highest risk should be used [1].
Notably, very recently (February 2013), the annually updated version of the GOLD Global Strategy for
Diagnosis, Management, and Prevention of COPD [6] has proposed that the Clinical COPD Questionnaire
(CCQ) [9] can also be used as an alternative to CAT to assess the symptomatic impact of the disease and
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FIGURE 1 Four patient categories (or groups) resulting from the application of the 2011 Global Initiative for Chronic
Obstructive Lung Disease (GOLD) assessment proposal [1]. For further details, see the main text. Although this is the
classification used for the four studies reviewed here [2–5], it is of note that the 2013 update [6] proposes to add (not
included in the figure) the Clinical COPD Questionnaire among the instruments that can be used to assess symptoms and
to consider as high risk any patient who has had at least one hospitalisation due to chronic obstructive pulmonary disease
(COPD) during the past year (also not included in the figure). mMRC: modified Medical Research Council dyspnoea
score; CAT: COPD Assessment Test score. Reproduced and modified from [6] with permission from the publisher.
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that one hospitalisation due to an exacerbation of COPD suffices to classify the patient into the ‘‘high-risk’’
groups (C and D). Yet, these changes were not considered by the four papers reviewed herein [2–5] because
they were published before the GOLD 2013 update release [6].
According to the results of this assessment, four patient groups (or categories) can be identified (fig. 1) [1].
It is important to note, however, that groups A and B are defined unequivocally according to risk (FEV1
o50% pred and no more than one exacerbation per year), so any given patient must fulfil these two criteria
to be classified in one of these two groups (fig. 1). This contrasts with groups C and D, which admit several
potential combinations. For instance, a given patient can be classified in group C because the presence of
fewer symptoms (by definition), and either FEV1,50% pred, or two or more exacerbations/year (or more
than one hospitalisation per year in the GOLD 2013 update [6]), or both (the same occurs with patients in
group D) (fig. 1). In fact, some of the studies discussed here [2, 5], but not the original GOLD document
[1], have named these three subgroups as C1, C2 and C3, and D1, D2 and D3, respectively (see later).
This combined assessment proposal [1] is expected to reflect the complexity of COPD better than the
unidimensional (FEV1) analysis previously used for staging the disease [8] and is therefore a potentially
important step forward towards a more personalised approach to COPD [10]. However, to some extent, it
is an empirical proposal based upon expert opinion and, hence, it requires experimental validation [1].
Besides, the categorisation is constructed to reflect different needs for management and, in contrast to the
old staging, categorisation may not necessarily reflect severity.
Published results on existing cohorts
COPDGene
The COPDGene study is a multicentre, observational investigation aimed at identifying genetic variants
related to COPD and thoracic computed tomography-defined COPD phenotypes [11]. An initial group of
4000 smokers (with and without COPD), including both non-Hispanic white American and African-
American individuals across all severities of airflow limitation, were recruited and assessed. Findings will be
verified in an additional 2000 COPD cases and 2000 smoking control subjects [11]. For the comparative
analysis discussed here, it is important to note that this study included participants not previously diagnosed
with COPD [11] and that such patients may have lower symptom levels, as assessed by instruments such as the
St George’s Respiratory Questionnaire (SGRQ), than patients diagnosed with COPD [12].
HAN et al. [2] used information from 4484 COPD patients (table 1) included in the COPDGene study to
investigate: 1) whether or not the two instruments proposed by the GOLD 2011 revision to assess the level
of symptoms of the patients (mMRC or CAT) produced similar results on patient group assignment (the
COPDGene study did not have CAT data, so the SGRQ (o25 versus ,25) was used as a surrogate for the
CAT threshold (o10 versus ,10, respectively) proposed by GOLD to classify patients in the ‘‘less’’ or
‘‘more’’ symptoms groups); and 2) the relationship of the four patient groups (A, B, C and D) with the
frequency of exacerbation recorded prospectively during telephonic follow-up (1.4 years).
Main results were as follows. 1) 33.6% versus 29.4% of patients were assigned to group A when the mMRC
or the SGRQ (as a surrogate of CAT) criteria were used, respectively (fig. 2). These percentages were 20.5%
versus 24.7% in group B, 7.9% versus 4.9% in group C, and 38.0% versus 41.0% in group D (k-coefficient
TABLE 1 Main demographic, clinical and functional variables of the chronic obstructive pulmonary disease (COPD) patients
included in each of the four studies analysed here
COPDGene [2] Copenhagen [3] Cocomics [4] ECLIPSE [5]
Subjects n 4484 6628 3163 2101
Recruitment source Hospitals General population 7 cohorts merged Hospitals
Country USA Denmark Spain Europe/USA
Age years 65 68 66 64
Males % 53 52 93 65
BMI kg?m-2 27 25 28 27
FEV1 % pred 40 40 54 50
Follow-up years 1.7 4.3 10 3
For further explanation, see the main text. Cocomics: Collaborative Cohorts to assess Multicomponent Indices of COPD in Spain; ECLIPSE:
Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints; BMI: body mass index; FEV1: forced expiratory volume in 1 s; % pred:
% predicted.
COPD ASSESSMENT | A. AGUSTI ET AL.
DOI: 10.1183/09031936.00036513 1393
for agreement 0.77) (fig. 2). 2) Depending on the specific risk factor used to determine category assignment
in the high-risk groups (FEV1 only (C1 and D1), previous exacerbation history only (C2 and D2) or both (C3
and D3)) (fig. 3), significant heterogeneity in prospective exacerbation rates was observed, particularly in
group D. In this latter group, the mean (95% CI) annual rate of exacerbations observed during follow-up in
the D1, D2 and D3 subgroups was, respectively, 0.89 (0.78–1.00), 1.34 (1.0–1.6) and 1.86 (1.6–2.1)
(p,0.0001).
From these results, HAN et al. [2] concluded that: 1) the instrument used to measure symptoms influences
category assignment; 2) the prevalence of group C patients (low symptoms and high risk) is low; and
3) exacerbation rates appear different depending on whether or not high-risk categorisation was based on
lung function, exacerbation history or both.
Copenhagen study
For this analysis, LANGE et al. [3] pooled data from two similar but independent general population studies:
the fourth examination of the Copenhagen City Heart Study (CCHS) from 2001–2003 and the examination
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of the Copenhagen General Population Study (CGPS) from 2003–2010. The CCHS is a prospective
epidemiological study that started in 1976–1978 and selected a random sample of subjects from the national
Danish Civil Registration System. A total of 14 223 residents of inner Copenhagen participated in the initial
survey [13], 6237 of whom attended the fourth survey in 2001–2003 [14]. The CGPS is a prospective
epidemiological study, the design of which is almost identical to the CCHS, aiming to recruit .100 000
individuals representative of the general population, and to collect genotypic and phenotypic data of
relevance to a wide range of health-related problems; recruitment began in 2003 and is still in progress [15].
Merging data from these two general cohorts, LANGE et al. [3] identified 6628 COPD patients (table 1) who
were monitored for .4 years for COPD exacerbations, hospital admissions and mortality. In this
convenience cohort, they sought to investigate the ability of the new GOLD 2011 assessment proposal
(using the mMRC criteria to categorise symptoms) to predict the clinical course of COPD [3].
The main results showed that: 1) the vast majority of patients in this study belonged to group A (fig. 2),
probably reflecting that this cohort of patients was identified from the general population; 2) the proportion
of patients experiencing a COPD exacerbation during the first year of observation increased progressively
from groups A to B to C to D (2.2%, 5.8%, 25.1% and 28.6%, respectively); and 3) at the 3-year follow-up,
mortality rates were 3.8%, 10.6%, 8.2% and 20.1% in groups A, B, C and D, respectively (fig. 4) [3].
Notably, groups B and D, both characterised by a higher degree of dyspnoea, had five to eight times higher
mortality from cardiovascular disease and cancer than groups A and C.
From these results, LANGE et al. [3] concluded that: 1) the new GOLD 2011 assessment proposal performs
well by identifying individuals at risk of exacerbations; and 2) despite being classified by GOLD as low risk,
patients in group B had significantly poorer survival than those in group C (classified as high risk). They
suggested that the poor prognosis of group B patients can be related to comorbidities, such as
cardiovascular disease or cancer, hence requiring special assessment and treatment [3]. An important aspect
of this study to consider is the fact that whereas GOLD recommendations relate to patients with a clinical
diagnosis of COPD, epidemiological studies rely heavily on spirometry.
Cocomics study
The Cocomics study is a pooled analysis of individual patient data (age, sex, mMRC score, post-
bronchodilator spirometry and all-cause mortality) from 11 COPD cohorts recruited in seven different
cities in Spain (Galdakao, Pamplona, Requena, Seville, Tenerife, Terrassa and Zaragoza) for different
purposes. In this pooled population (table 1), SORIANO et al. [4] sought to: 1) determine the distribution of
the four groups proposed by the GOLD 2011 revision; and 2) compare its validity in predicting all-cause
mortality up to 10 years, as compared to the previous GOLD staging system based mostly on the FEV1 value
alone. Other outcomes, namely exacerbations, were not reliably recorded and were not included in the
analysis [4].
The main results were as follows. 1) Of the 3633 patients included in the analysis, 1064 (33.6%) were
classified as group A, 515 (16.3%) as group B, 561 (17.7%) as group C and 1023 (32.3%) as group D
(fig. 2). This distribution, however, varied significantly (Chi-squared p,0.01) between the 11 cohorts
pooled [4]. 2) The ability of GOLD 2007 to predict mortality was not different from that of GOLD 2011 at
1 year (0.635 versus 0.639, p50.53), 3 years (0.637 versus 0.645, p50.21) or 10 years (0.639 versus 0.642,
p50.76). Again, however, survival varied greatly between cohorts [4].
From these results, SORIANO et al. [4] concluded that: 1) the GOLD 2011 assessment proposal results in an
uneven split of the COPD population; and 2) its capacity to predict mortality is no different from the old
GOLD staging approach based in FEV1 only. It should be remembered, however, that the multidimensional
GOLD assessment proposal was put forward to provide a structured assessment to guide treatment directed
towards symptoms and exacerbations, not to provide a prognostic marker of mortality.
ECLIPSE study
ECLIPSE is a multicentre, international, longitudinal study aimed at identifying clinically relevant COPD
subtypes (phenotypes) and the genetic factors and/or biomarkers that correlate with them and predict
disease progression [16]. ECLIPSE included 2164 clinically stable COPD patients, 337 smokers with normal
lung function and 245 never-smokers, who were extensively characterised and followed up for 3 years [7].
AGUSTI et al. [5] explored the distribution, characteristics, temporal stability and relationship with outcomes
(exacerbations, hospitalisations and all-cause mortality) of 2101 COPD patients with complete mMRC,
spirometry and previous exacerbation history according to the 2011 GOLD assessment proposal (table 1).
The main results were as follows. 1) In addition to the expected differences between groups in the three
variables that define them (mMRC, FEV1 and previous exacerbations), the four groups differed also in
many other clinical characteristics studied (table 2). Hence, pulmonary emphysema and arterial
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oxygenation impairment were particularly prevalent in the two high-risk categories (groups C and D)
whereas comorbidities and persistent systemic inflammation were worse in the two highly symptomatic
categories (groups B and D). By contrast, age, sex, FEV1 reversibility and FEV1 decline were not different
between groups, although the latter was numerically higher in patients in the B category (table 2) [5]. 2) An
FEV1 ,50% pred was the most frequent determinant of being classified as a group C (C1, 70%) or D (D1,
63%) patient, whereas a history of frequent exacerbations exclusively was the least prevalent (subgroups C2
(13%) and D2 (9%)) (fig. 3). 3) Group A and D patients were relatively stable over time, whereas those in
groups B and C showed marked variability, some patients improving and others deteriorating during
follow-up [5]. 4) Finally, the incidence of exacerbations during follow-up increased progressively (p,0.001)
from groups A to B to C to D [5]. By contrast, and similar to the findings of LANGE et al. [3] in the
Copenhagen study, hospitalisations (fig. 4) and all-cause mortality were lowest in group A, highest in group
D (pf0.010), and intermediate but similar in groups B and C [5]. Notably, in this context, group B patients
had less severe airflow limitation than group C patients but the highest prevalence of comorbidities (table 2)
and persistent systemic inflammation [7].
From these results, AGUSTI et al. [5] concluded that: 1) there is significant clinical heterogeneity across the
four GOLD 2011 groups; 2) the two extreme categories (A and D) were relatively stable over time but the
two intermediate ones (groups B and C) show greater temporal variability, probably in relation to disease
progression and/or response to therapy; 3) the new GOLD assessment proposal is feasible and valid for
assessing the risk of future exacerbations (which increase steadily from groups A to B to C to D) but does
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not discriminate the risk of future hospitalisations and all-cause mortality for group B and C patients,
probably highlighting the importance of symptom (and comorbidity) assessment in clinical practice.
Frequently asked questions
The comparative analysis of these four studies [2–5] helps us to respond some FAQs regarding the GOLD
assessment proposal but poses other questions that will inevitably require further research.
What is the prevalence of these four groups?
The answer depends on the population studied (fig. 2). In the general population, the most prevalent group
is A (77%) [3], whereas in patients recruited from secondary and tertiary care, it is D (37%) followed closely
by, surprisingly, A (32%) [2, 4, 5]; the prevalence of group B is ,20% and, clearly, group C is the least
prevalent (10%), although it is also the one with the highest variability between studies (fig. 2).
Does the instrument used to determine the level of symptoms matter?
HAN et al. [2] compared the mMRC and SGRQ scores (as a surrogate of CAT) in COPDGene and
concluded that concordance between the two was good (k50.77) but the distribution of the four groups
(fig. 2) was significantly different. In a more recent European study in primary care, a direct comparison of
mMRC and CAT showed lower concordance (k50.63) between the two instruments [17]; yet, agreement
improved (k50.79) if mMRC o1 was used as the cut-point instead of the threshold suggested by GOLD
(o2) [1]. However, if a broader perspective is taken (fig. 2), the impact of the specific instrument used to
determine the level of symptoms may be no greater than other potential confounders, such as the specific
type of cohort studied. In any case, a standardised approach would be desirable if future clinical studies are
to be compared. In this context, it is worth noting that, although historically, there are a lot of data using
TABLE 2 The main clinical characteristics and associated outcomes of the four Global Initiative for Chronic Obstructive Lung
Disease (GOLD) 2011 categories in the ECLIPSE cohort [7]
Distribution GOLD 2011 groups p-value
A B C D
GOLD 2011 assessment variables
mMRC dyspnoea score 0.6 2.3 0.8 2.6 ,0.001
FEV1 % pred 64.2 61.6 42.2 37.2 ,0.001
Exacerbations previous 12 months n 0.2 0.3 1.0 1.3 ,0.001
Demographics
Age years 63.2 64.1 62.9 63.6 NS
Females % 39 36 31 34 NS
BMI kg?m-2 26.7 28.5 25.2 26.5 ,0.001
Smoking pack-years 48.0 47.5 45.2 51.1 ,0.001
Current smokers % 38 34 43 32 0.001
Symptoms and comorbidities
Chronic bronchitis % 26 35 38 38 ,0.001
SGRQ-C total score 31.9 55.3 44.6 62.2 ,0.001
Comorbidities n 2.0 2.8 1.7 2.3 ,0.001
Physiology and imaging
FEV1 reversibility % 11.4 11.8 10.3 10.2 NS
SaO2 % 95.7 95.1 94.4 93.7 ,0.001
6MWD m 440 360 408 307 ,0.001
Emphysema CT LLA# % 11.8 12.5 18.9 22.5 ,0.001
Outcomes during follow-up"
ECOPDs per year n 0.6 0.9 1.3 1.7 ,0.001
o1 hospitalisation % 11 25 30 46 ,0.001
Mortality rate % 4 10 8 14 ,0.001
Rate of FEV1 decline mL?year-1 -33.4 -38.0 -30.2 -31.9 NS
Data are presented as mean values. For further explanation, see the main text. COPD: chronic obstructive pulmonary disease; ECLIPSE: Evaluation
of COPD Longitudinally to Identify Predictive Surrogate Endpoints; mMRC: modified Medical Research Council; FEV1: forced expiratory volume in
1 s; % pred: % predicted; BMI: body mass index; SGRQ-C: St George’s Respiratory Questionnaire for COPD Patients; SaO2: arterial oxygen
saturation; 6MWD: 6-min walk distance; CT: computed tomography; LAA: low-attenuation area; ECOPD: exacerbation of COPD; NS: nonsignificant.
#: -950 HU; ": 3 years. Reproduced and modified from [5].
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the Medical Research Council scale, this instrument reflects only one aspect of COPD (i.e. breathlessness),
whereas the CAT and the CCQ (now included in the GOLD 2013 revision [6]) are more comprehensive.
Do these groups differ in other clinical characteristics than those used for their own definition?
Three studies [2, 3, 5] identified differences between groups besides those used for their own definition
(table 2). For instance, in ECLIPSE, the prevalence of comorbidities and systemic inflammation was highest
in the high-symptom groups (B and D), whereas the presence of emphysema and lower arterial oxygen
saturation was highest in the high-risk groups (C and D) [5]. By contrast, other potentially relevant clinical
variables, including age, sex and FEV1 reversibility, were not different across groups [5]. The precise nature
of these comorbidities in ECLIPSE has been described in detail elsewhere [7] but includes the most
prevalent ones, such as cardiovascular disease, metabolic syndrome, osteoporosis and depression [18].
Are there distinct subgroups in high-risk categories?
Three studies [2, 3, 5] explored this question and came to very similar conclusions. The most frequent
reason to categorise a given patient as high risk (i.e. groups C and D) was an FEV1 ,50% pred (C1 or D1)
(fig. 3). By contrast, that a patient was considered high risk based only on the previous history of
exacerbations (i.e. with an FEV1 .50% pred; C2 or D2) was relatively rare (fig. 3). The implications of these
differences in terms of prognosis or optimal care deserve future research.
Do these four groups of patients remain stable over time?
Only the ECLIPSE study addressed this question [5]. The results showed that the relative majority of
patients assigned to groups A and D continue to belong to these same two groups 3 years later, whereas
those classified in groups B or C tend to vary more (fig. 5). The mechanisms explaining these temporal
changes (or lack of changes) also deserve future research but they are probably related to either so-called
disease progression or response to therapy. Importantly, these findings show that there is also heterogeneity
in the disease progression, which might present opportunities for therapeutic intervention [6].
Do these four groups predict mortality?
The GOLD assessment proposal was not designed to predict mortality. Yet, the four GOLD categories do
indeed relate to mortality, albeit in a surprising manner. Both LANGE et al. [3], in the general population
recruited in Copenhagen, and AGUSTI et al. [5], in the ECLIPSE cohort, found that survival at 3 years was
better for patients in group A, worse for group D, and intermediate and similar for groups B and C (fig. 3).
This is consistent with previous studies on the prognostic importance of symptom perception [19]. In
Cocomics, survival at 3 years was also similar in groups B and C, but results changed after 10 years’ follow-
up (fig. 4) [4], perhaps indicating a survival bias.
With respect to the precise causes of death in these four patient categories, LANGE et al. [3] showed that
groups B and D (both ‘‘high symptoms’’) had five to eight times higher mortality from cardiovascular
disease and lung cancer than the fewer-symptoms groups (A and C). Specific causes of death were not
investigated in COPDGene [2] or Cocomics [4], whereas in ECLIPSE, Cox proportional hazards regression
analysis identified a number of factors associated with increased risk of mortality (severity of airflow
limitation, older age, lower body mass index, increased number of comorbidities and lower exercise
capacity) [5]. This information may help clinicians to assess the risk of death in individual patients.
Do these four groups of patients predict exacerbations/hospitalisations?
All four studies showed that the incidence of exacerbations increases progressively from A to B to C to D
[2–5]. This is not surprising, as the history of previous exacerbation, the best current predictor of future
exacerbations [20], is one of the variables used to define these four groups [1]. By contrast, the capacity to
predict hospitalisations was explored in ECLIPSE only [5] and, like mortality (see earlier), hospitalisations
during follow-up were scant in group A, frequent in group D, and intermediate (and similar) in groups B
and C patients. Furthermore, identified risk factors for hospitalisations were similar to those identified for
mortality (see earlier) [5].
Why do groups B and C appear to have similar risk of death/hospitalisation?
Both LANGE et al. [3] and AGUSTI et al. [5] suggested that high symptoms in group B may originate from
comorbidities and not from airflow limitation. In fact, LANGE et al. [3] showed in the general population
that group B patients frequently die of cardiovascular disease or lung cancer. Likewise, in the ECLIPSE
cohort, group B patients were also characterised by the highest prevalence of comorbidities and presence of
persistent systemic inflammation [5]. The former is known to have a direct and significant impact on
survival in COPD [21] while the latter has been recently shown to increase mortality six-fold irrespective of
the severity of the underlying pulmonary abnormalities [22]. All in all, these observations highlight that
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COPD patients may need hospitalisation (or die) during follow-up for reasons not directly related to their
lung function (e.g. comorbidities) and support the GOLD recommendation on the importance of actively
assessing (and treating if present) the most frequent comorbidities in these patients [1].
Do these four groups have different rates of annual lung function decline?
ECLIPSE addressed this question and showed that there were no significant differences in the rate of lung
function decline between the four groups (table 2) [5]. This lack of differences suggests that further
segmentation of the COPD population beyond that proposed by GOLD may be required to better describe
COPD heterogeneity in full [5].
Do these groups have different patterns and/or severity of comorbidities?
Comorbidities appear to be more prevalent in group B patients [3, 5] and, as discussed above, they may
contribute to the increased risk of hospitalisations and death in this group (fig. 4). Notably, however, in the
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FIGURE 5 Temporal stability of the four patient categories in the Evaluation of COPD Longitudinally to Identify
Predictive Surrogate Endpoints. Boxes with percentages indicate the proportion of baseline patients available for
examination at the 3-year follow-up. For further explanation, see the main text. #: death/drop-out/lost for follow-up/
missing data. Reproduced from [5].
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four studies reviewed here [2–5], comorbidities were either identified from medical records or self-reported,
but not actively identified by clinical investigations [23]. This may be clinically relevant, as most
comorbidities are undiagnosed. Despite that the new GOLD recommendations [1] clearly highlight the
important role of comorbidities in COPD [21, 23, 24], a current challenge is how to incorporate them
explicitly in the proposed assessment diagram. Ongoing discussion is addressing the importance of
comorbidities for the definition of COPD severity and how to incorporate them in the A–D diagram or a
different diagram [25].
Do these four groups of patients require different therapeutic strategies?
To date, there are no studies where patients have been investigated on the basis of the A–D categorisation as
inclusion criteria; the four studies reviewed here [2–5] are observational and none tested the effect of any
particular therapeutic intervention. Therefore, from this comparative analysis, no specific therapeutic
recommendations can be made to support or refute those provided by GOLD, which are the result of expert
consensus based on previous randomised clinical trials (RCTs). Hopefully, this much-needed evidence will
become available in the near future either by retrospective analysis of already published RCTs or, ideally, by
new prospective ones.
Strengths and limitations of this analysis
As in any analysis, the current one has strengths and shortcomings. Among the former, this is the first paper
comparing four recent studies [2–5] that, in turn, explore several relevant aspects related to the potential
validations of the recent GOLD recommendations [1]. Hence, the results of the current analysis can be of
importance for the translation of the GOLD recommendations into practice, for the design of future studies
and for the eventual refinement of the GOLD document itself. However, several limitations need to be
acknowledged. Firstly, the analysis compares four studies, all of which use existing cohorts of COPD
patients that were established for different purposes, so results will have to be replicated prospectively in
other populations. Secondly, all of the included studies used observational cohorts, so in none of them was
treatment controlled; rather, it was dictated by the local physician taking care of the patient [2–5]. More
importantly, all patients were treated, so these are not studies describing the ‘‘natural history of COPD’’ but
the natural history of treated COPD.
Conclusions
This comparative analysis identifies a number of similarities and differences across four recently published
studies [2–5] that investigated the clinical implications of the new GOLD recommendations [1]. From this
analysis, a number of FAQs can be addressed but other new questions arose that may require further research.
Altogether, though, the results discussed herein constitute a repository of potentially useful information for
practitioners, investigators, administrators, regulators, stakeholders and guideline writers. However, it is now
time for new studies to be designed and performed prospectively in these four patient groups, both to relate
them to severity and prognosis and/or comorbidities, and to assess their response to treatment.
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